secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001213900-25-002644
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO William Febbo departs OptimizeRx; receives $675K salary continuation + $450K bonus
--------------------------------------------------------------------------------

- William J. Febbo stepped down as CEO and Board member effective Dec 31, 2024; separation agreement signed Jan 3, 2025.
- Severance includes $450k/yr base salary for 18 months ($675k total) and a lump-sum $450k bonus.
- COBRA premium reimbursement for 12 months; advisory services through March 31, 2025 with continued equity vesting.
- 12-month non-compete and non-solicit obligations apply; no replacement CEO named yet.
- Equity awards continue to vest during the 3-month advisory period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/0001213900-25-002644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/ea0227345-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-002644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer